Lindahl advises Disruptive Pharma in connection with reverse acquisition

Through the transaction, Disruptive Pharma gains access to the capital markets and a platform for the continued development and commercialisation of the company's patent-protected technology Formulite®. Provided that all outstanding shares in Disruptive Pharma are acquired, Disruptive Pharma's shareholders will, following completion of the transaction, hold approximately 55 per cent of the shares and votes in the combined company. Following completion of the transaction, Disruptive Pharma's operations will constitute the company's principal business. In connection with the transaction, Guard Therapeutics also intends to change its name to Disruptive Pharma AB.

The transaction is conditional upon, inter alia, approval by the shareholders of Guard Therapeutics, approval for continued listing on Nasdaq First North Growth Market, that the transaction is approved or left without action by the Inspektionen för strategiska produkter (ISP) in accordance with the Act (2023:560) on the Review of Foreign Direct Investments, and other customary conditions.

Lindahl's team consisted principally of Erika Svensson, Michaela Larsson and Theo Biström.

Read more in Guard Therapeutics' press release here. 

About our client Disruptive Pharma

Disruptive Pharma is a Swedish pharmaceutical and technology company that develops and commercialises the patent-protected and clinically validated platform technology Formulite®, based on mesoporous magnesium carbonate (MMC). The technology addresses key challenges in pharmaceutical development, such as low solubility, limited oral bioavailability and other properties that affect the clinical and commercial potential of drug candidates. The company was founded in 2021 as a spin-off from Disruptive Materials AB and has its origins in world-leading research at Uppsala University, led by Professor Maria Strømme.